Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of Interim Chief Strategy Officer
On May 4, 2017, the board of directors (the “Board”) of Integrity Applications, Inc., a Delaware Company (the “Company”), unanimously voted to appoint Angela Strand, a member of the Board, as the interim Chief Strategy Officer of the Company, effective as of May 1, 2017 through September 30, 2017 (the “Term”).
On May 5, 2017, the Company entered into a letter agreement (the “Strand Employment Agreement”) with Ms. Strand confirming her appointment as interim Chief Strategy Officer of the Company during the Term. to the terms of the Strand Employment Agreement, Ms. Strand will receive compensation of $150,000 for the Term, paid monthly on the schedule mutually agreed upon by the parties.
Ms. Strand has served as one of the Company’s directors since March 2016 and was appointed Vice Chairperson of the Board in March 2017. Ms. Strand is a member of the Compensation Committee of the Board and is Chairperson of the Nominating and Corporate Governance Committee of the Board. Ms. Strand is a founder of Nohm, a joint venture between Smith Electric Vehicles and FDG Electric Vehicles Ltd. (HK: 729HK), and was a senior executive at Nohm from June, 2015 to December, 2016. Ms. Strand is the founder of Strand Strategy, a healthcare management and consulting firm (“Strand Strategy”) and is also a named inventor with seven issued patents. From 2011-2015, Ms. Strand served as the chief marketing officer and head of business development and government affairs for Smith Electric Vehicles. Ms. Strand has also served as vice president of market development for Proteus Digital Health, and in various leadership and executive roles at Aerogen (acquired by Nektar Therapeutics, NASDAQ:NKTR), Novacept (acquired by Cytyc, NASDAQ: CYTC, now NASDAQ: HOLX) and FemRx (acquired by Johnson & Johnson, NYSE: JNJ). Ms. Strand holds a B.Sc. in Communications and an MBA in Marketing from the University of Tennessee. Ms. Strand is 48 years old.
Ms. Strand has no family relationships with any of the executive officers or directors of the Company. Except as set forth below, the Company is not aware of any transactions since the beginning of its last fiscal year or any proposed transactions in which the Company was or is a party, in which (1) the amount involved exceeded the lesser of $120,000 or 1% of the average of the Company’s total assets at year-end for the last two completed fiscal years and (2) a director, director nominee, executive officer, holder of more than 5% of the Company’s common stock or preferred stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.
As previously reported in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 6, 2017, on February 6, 2017, the Company entered into an amended and restated consulting agreement with Strand Strategy (the “A&R Consulting Agreement”) relating to the retention of Strand Strategy’s services as an independent contractor on a temporary basis, effective as of December 1, 2016 (the “Effective Date”). Ms. Strand is the founder and managing director of Strand Strategy. to the terms of the A&R Consulting Agreement, Strand Strategy assisted the Company with its corporate strategy, business development and communication management for a 90-day period, beginning on the Effective Date (the “Services”). As consideration for the Services, the Company paid Strand Strategy a fee of $60,000, 25% of which was paid in cash and 75% of which was paid by the grant to Strand Strategy of 10,000 shares of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The A&R Consulting Agreement contained confidentiality obligations that survive the termination of the A&R Consulting Agreement indefinitely. The terms of the A&R Consulting Agreement expired on February 28, 2017.
As previously reported in a Current Report on From 8-K filed by the Company with the Securities and Exchange Commission on March 24, 2017, on March 20, 2017, the Board authorized the payment of $20,000, 25% of which was paid in cash and 75% of which was paid by the grant of 3,334 shares of Common Stock to Strand Strategy as additional consideration for the consulting services provided by Strand Strategy to the Company for the month of March, 2017. The Company had originally agreed to such services, to the A&R Consulting Agreement, but the term of such agreement expired on February 28, 2017.
2
About Integrity Applications, Inc. (OTCMKTS:IGAP)
Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood. Integrity Applications, Inc. (OTCMKTS:IGAP) Recent Trading Information
Integrity Applications, Inc. (OTCMKTS:IGAP) closed its last trading session 00.00 at 2.00 with 2,000 shares trading hands.
Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood. Integrity Applications, Inc. (OTCMKTS:IGAP) Recent Trading Information
Integrity Applications, Inc. (OTCMKTS:IGAP) closed its last trading session 00.00 at 2.00 with 2,000 shares trading hands.